Valentina Andreasi

List of Publications by Citations

42 papers	380 citations	12 h-index	17 g-index
45 ext. papers	619 ext. citations	3.7 avg, IF	3.72 L-index

#	Paper	IF	Citations
42	The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms. *European Journal of Surgical Oncology*, **2018**, 44, 778-783	3.6	38
41	A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients. *Annals of Surgery*, **2019**, 270, 422-433	7.8	33
40	CT-derived radiomic features to discriminate histologic characteristics of pancreatic neuroendocrine tumors. *Radiologia Medica*, **2021**, 126, 745-760	6.5	27
39	Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?. *Annals of Surgical Oncology*, **2020**, 27, 1348-1355	3.1	26
38	A Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. *Hpb*, **2018**, 20, 197-203	3.8	20
37	Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: Limitations to apply guidelines into real life. *Surgery*, **2019**, 166, 157-163	3.6	19
36	Is the Real Prevalence of Pancreatic Neuroendocrine Tumors Underestimated? A Retrospective Study on a Large Series of Pancreatic Specimens. *Neuroendocrinology*, **2019**, 109, 165-170	5.6	16
35	Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3. *American Journal of Surgery*, **2020**, 220, 284-289	2.7	14
34	Ct radiomic features of pancreatic neuroendocrine neoplasms (panNEN) are robust against delineation uncertainty. *Physica Medica*, **2019**, 57, 41-46	2.7	14
33	Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors. *Neuroendocrinology*, **2021**, 111, 273-287	5.6	13
32	Combined 68Ga-DOTA-peptides and 18F-FDG PET in the diagnostic work-up of neuroendocrine neoplasms (NEN). *Clinical and Translational Imaging*, **2019**, 7, 181-188	2	12
31	Implications of increased serum amylase after pancreaticoduodenectomy: toward a better definition of clinically relevant postoperative acute pancreatitis. *Hpb*, **2020**, 22, 1645-1653	3.8	12
30	DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. *Scientific Reports*, **2019**, 9, 18614	4.9	12
29	Diagnostic strategy with a solid pancreatic mass. *Presse Medicale*, **2019**, 48, e125-e145	2.2	11
28	A systematic review and meta-analysis on the role of omental or falciform ligament wrapping during pancreaticoduodenectomy. *Hpb*, **2020**, 22, 1227-1239	3.8	11
27	Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment. *Nuclear Medicine Communications*, **2020**, 41, 896-905	1.6	11
26	The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age. *Digestive and Liver Disease*, **2019**, 51, 735-740	3.3	10

25	Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors. *Annals of Surgical Oncology*, **2020**, 27, 3928-3936	3.1	10
24	Long-Term Pancreatic Functional Impairment after Surgery for Neuroendocrine Neoplasms. *Journal of Clinical Medicine*, **2019**, 8,	5.1	7
23	Local treatment for focal progression in metastatic neuroendocrine tumors. *Endocrine-Related Cancer*, **2019**, 26, 405-409	5.7	7
22	Preoperative predictive factors of laparoscopic distal pancreatectomy difficulty. *Hpb*, **2020**, 22, 1766-1774	3.8	7
21	Update on gastroenteropancreatic neuroendocrine tumors. *Digestive and Liver Disease*, **2021**, 53, 171-182	3.3	7
20	A Preoperative Clinical Risk Score Including C-Reactive Protein Predicts Histological Tumor Characteristics and Patient Survival after Surgery for Sporadic Non-Functional Pancreatic Neuroendocrine Neoplasms: An International Multicenter Cohort Study. *Cancers*, **2020**, 12,	6.6	6
19	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. *Surgical Oncology*, **2020**, 35, 141-148	2.5	6
18	Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET). *Pancreatology*, **2019**, 19, 57-63	3.8	5
17	68Ga-DOTA-peptides PET/MRI in pancreatico-duodenal neuroendocrine tumours: a flash pictorial essay on assets and lacks. *Clinical and Translational Imaging*, **2019**, 7, 363-371	2	4
16	How should incidental NEN of the pancreas and gastrointestinal tract be followed?. *Reviews in Endocrine and Metabolic Disorders*, **2018**, 19, 139-144	10.5	4
15	Dual Tracer 68Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms. *Diagnostics*, **2021**, 11,	3.8	4
14	Prognostic Role of Examined and Positive Lymph Nodes after Distal Pancreatectomy for Non-Functioning Neuroendocrine Neoplasms. *Neuroendocrinology*, **2021**, 111, 728-738	5.6	3
13	Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms. *Current Treatment Options in Oncology*, **2020**, 21, 48	5.4	3
12	The role of acinar content at pancreatic resection margin in the development of postoperative pancreatic fistula and acute pancreatitis after pancreaticoduodenectomy. *Surgery*, **2021**, 170, 1215-1222	3.6	3
11	Diagnostic accuracy of EUS-FNA in the evaluation of pancreatic neuroendocrine neoplasms grading: Possible clinical impact of misclassification. *Endoscopic Ultrasound*, **2021**, 10, 372-380	3.6	2
10	EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). *Cancers*, **2021**, 13,	6.6	1
9	Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors. *Surgery*, **2020**, 168, 816-824	3.6	1
8	Evaluation of cost-effectiveness among open, laparoscopic and robotic distal pancreatectomy: A systematic review and meta-analysis. *American Journal of Surgery*, **2021**, 222, 513-520	2.7	1

7	How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery.. *Current Oncology Reports*, **2022**, 24, 227	6.3	0
6	Evaluation of factors predicting loss of benefit provided by laparoscopic distal pancreatectomy compared to open approach. *Updates in Surgery*, **2021**, 1	2.9	0
5	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.. *JAMA Network Open*, **2022**, 5, e220290	10.4	0
4	Guideline for the Management of Pancreatic Neuroendocrine Tumor **2017**, 161-172		
3	Diagnosis and Treatment of Pancreatic Neuroendocrine Tumors **2021**, 631-640		
2	New Surgical Strategies **2021**, 113-128		
1	Non Functional Pancreatic Neuroendocrine Tumors **2021**, 125-135		